Search company, investor...
Esaote company logo


Founded Year



Acq - Fin - II | Alive



About Esaote

Esaote is a producer of medical diagnostic systems, including ultrasound and MRI equipment.

Headquarters Location

Via E. Melen, 77

Genoa, 16152,


+39 010 6547 1

Missing: Esaote's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Esaote's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Esaote

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Esaote is included in 4 Expert Collections, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)


Health Monitoring & Diagnostics

380 items

Companies developing technology to facilitate point-of-care (POC) diagnostic imaging. Excludes intraoperative imaging. Companies tagged as #PointOfCareImaging


Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

363 items

Esaote Patents

Esaote has filed 112 patents.

The 3 most popular patent topics include:

  • Medical imaging
  • Medical ultrasonography
  • Image processing
patents chart

Application Date

Grant Date


Related Topics




Medical ultrasonography, Medical imaging, Prosthetics, Medical equipment, Implants (medicine)


Application Date


Grant Date



Related Topics

Medical ultrasonography, Medical imaging, Prosthetics, Medical equipment, Implants (medicine)



Latest Esaote News

Esaote Presents the World Premiere of Its New Mylab X90 Ultrasound Device

Jan 30, 2023

Share Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical IT– presents the world premiere of MyLabX90, its new premium ultrasound system. “Accuracy and precision across the entire image generation chain, data processing speed and native AI-based application management lie at the heart of MyLab™X90,” said  Guillaume Gauthier , Ultrasound Global Product Marketing Manager. “As well as providing high-quality images and advanced clinical solutions, our aim was to revolutionize daily workflows by increasing the speed and accuracy of analysis, together with improving the operator experience and the clinical outcome for patients.” MyLab X90 offers premium components, where the starting points are the renewal of the XCrystal probe family and the exclusive dual-layer eLed monitor by Barco. These ensure outstanding on-screen image display at a very high contrast resolution, far superior to other product lines. Related Posts Jan 30, 2023 MyLab™X90 also offers advanced ergonomics in clinical solutions focused on the operator, which extend data analysis capacity and ensure a unique customer experience based on diagnostic confidence, as well as on automation to improve the usability and availability of advanced technologies in everyday clinical practice. “We are highly satisfied with this outcome, the result of substantial investment and intense work on R&D. The new MyLabX90, with its all-Italian design, represents a further evolution in the range of technologies we provide to assist with people’s care and well-being,” noted Franco Fontana, CEO of Esaote. “It represents the upshot of strategic investment and of our international, multidisciplinary team, who can tackle the challenges of innovation and anticipate requirements in the most advanced and interconnected healthcare systems. We believe that these aspects, combined with the latest technologies, can contribute significantly to improving the level of patient care, and are delighted to play an active role.”]

Esaote Frequently Asked Questions (FAQ)

  • When was Esaote founded?

    Esaote was founded in 1982.

  • Where is Esaote's headquarters?

    Esaote's headquarters is located at Via E. Melen, 77, Genoa.

  • What is Esaote's latest funding round?

    Esaote's latest funding round is Acq - Fin - II.

  • Who are the investors of Esaote?

    Investors of Esaote include Yunfeng Capital, Yuwell Medical, Tianyi Group, Shanghai Free Trade Zone Equity Fund Management, Beijing Wandong Medical and 8 more.

  • Who are Esaote's competitors?

    Competitors of Esaote include Binx Health, Insight Imaging, Armune Bioscience, Signostics, Profound Medical and 13 more.

Compare Esaote to Competitors

CMC Contrast

CMC Contrast AB was established in April 2000 with the purpose to develop targeted contrast media for MRI.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

ADNAvance Technologies

Adnavance Technologies Inc is developing enabling technology applications that use the conductivity properties of both normal and novel metallic forms of DNA aimed at large biosensormolecular diagnostics and energy generationmanagement markets

LUX biotechnology

LUX biotechnology (LUX) develops and distributes high quality calibration tools and reagents for luminescence and fluorescence applications.

Body Surface Translations

Body Surface Translations is a biomedical device company focused on discovery and marketing of imaging technology that can be used to estimate the weight of an animal. The initial target markets will be agribusiness (swine and cattle) but opportunities in other aspects of agriculture and human health are envisioned as well.

Nanoprobes Logo

Nanoprobes was founded to develop the most sensitive reagents and technology for detecting biological molecules. The company's gold labeling technology uses chemically cross-linked metal clusters and nanoparticles as labels. Unlike conventional immunogold probes, in which colloidal gold particles are electrostatically adsorbed to antibodies and proteins, the company's gold labels are uncharged molecules which are cross-linked to specific sites on biomolecules. This aims to give the company's probes a range and versatility which is not available with colloidal gold. The company's labels can be attached to any molecule with a reactive group -- proteins, peptides, oligonucleotides, small molecules and lipids -- for detection and localization. Other labels can be combined with the company's gold labels; the company's FluoroNanogold probes combine Nanogold and fluorescein into a single probe for imaging a specimen both by fluorescence and electron microscopy. New probes can be engineered based on any fragment of a naturally occurring biomolecule, and the label can be positioned away from the binding site so it does not interfere with binding. The company's 1.4 nm Nanogold probes have been cited in over 80 publications, and the company are now developing larger cross-linkable labels in order to offer the company's customers larger covalently linkable probes with the same advantages.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.